Skip to main content

Christina Scott

Associate

[email protected]

+1.617.348.3021

Share:

Christina focuses her intellectual property practice on patent litigation before federal district courts. She works with clients across the life sciences sector, including biotechnology, medical device companies, and pharmaceutical companies. Christina was a Summer Associate at Mintz in 2023.

 

While earning her JD, Christina interned with a biotechnology company, where she assisted with office actions before the US Patent and Trademark Office involving biotechnology device patents, conducted trademark clearance searches, and reviewed client contracts and non-disclosure agreements. Christina also served as senior editor of the University of New Hampshire Law Review and was elected director of communication and events in the Student Intellectual Property Law Association (SIPLA). Christina received her Intellectual Property Law Certificate alongside her JD at UNH Franklin Pierce School of Law.

 

Before attending law school, Christina was a post-baccalaureate pharmacology analysis fellow for the US Food and Drug Administration. In that role, she extracted secondary pharmacology assay data from Investigational New Drug (IND) applications, which are submitted by large pharmaceutical companies and used to assess a drug candidate’s potential to induce adverse side effects. 

 

While earning a BS in Chemistry with a concentration in Medicinal Chemistry and Drug Discovery, Christina was on a research team that explored the functionality of a superfamily of radical SAM enzymes. She also has experience in chromatography, in-vitro cell culture growth, and gel electrophoresis.

News & Press

News Thumbnail Mintz

Life sciences trade secret cases continue to climb, driven by evolving restrictions on certain types of patents and patent litigation, a spike in companies’ use of confidential data, and increased employee mobility — and changes linked to the 2016 Defend Trade Secrets Act. In an article for IAM, Member Tom Wintner and Associate Nick Armington explain how these trends are shaping IP protection in the sector.

Read less

Publications

  • Co-author, Aggregation and Analysis of Secondary Pharmacology Data From Investigational New Drug Submissions at the US Food and Drug Administration, Pharmacol Toxicological Methods (July 2021)
  • Co-author, Analysis of Secondary Pharmacology Assays Received by the US Food and Drug Administration, Pharmacol Toxicological Methods (August 2022)
  • Author, A Drug's Life: The Untapped Potential of Secondary Pharmacology Studies in Drug Development, The University of New Hampshire Law Review (June 2024)
Read less